Cited by 44Allergic Rhinitis and SensitizationAsthma and respiratory diseasesFood Allergy and Anaphylaxis Research

Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis

Open access
Walter Canonica, G., Bousquet, Jean, Van Hammée, Geneviève, Bachert, Claus, Durham, Stephen R., Klimek, Ludger, Mullol, Joaquim, Van Cauwenberge, Paul B.·2006·Respiratory Medicine

Abstract

Background Allergic rhinitis is a chronic respiratory disorder with a detrimental impact on health-related quality of life (HRQOL) and health status. Enhancement and maintenance of patient function and well-being are therefore considered as essential.Objective To determine whether long-term treatment with levocetirizine 5mg improves HRQOL and health status in persistent allergic rhinitis (PER) patients assessed with RQLQ and SF-36 scales over a 6-month period.Methods The Xyzal in PER Trial (XPERT) was a multi-center, double-blind, parallel-group study. A total of 551 patients were randomized to receive levocetirizine 5mg or placebo once daily for 6 months and assessed for symptoms, HRQOL (Rhinoconjunctivitis Quality of Life Questionnaire: RQLQ) and health status (SF-36). Sensitivity of the RQLQ and SF-36 to disease severity was tested to ensure their suitability for use in PER patients. Treatment effect was assessed by means of repeated measures analyses.Results Over the 6-month treatment period, levocetirizine showed statistically significant improvements over placebo in HRQOL (P < 0.001 for all RQLQ domains and overall scores) and health status (P < or = 0.004 for SF-36 physical and mental summary scores; P < 0.05 for all SF-36 scales). The relative improvement of levocetirizine over placebo exceeded the predefined clinically meaningful threshold of 30% for all RQLQ scores and the improvement from baseline was 3 times the established MID for RQLQ.Conclusion The RQLQ and SF-36 could be used to measure HRQOL and health status in PER patients. Long-term treatment with levocetirizine provides sustained improvement of HRQOL and reduces disease burden in PER patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2006.03.039

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two randomized controlled trials of levocetirizine over 6 months showed that both placebo and treatment groups experienced clinically and statistically significant improvements in generic and disease-specific quality of life, with greater improvement in the treatment arm.

    “These RCTs show that over a 6-month period, both the placebo and treatment group experience clinically and statistically significantly improvements in generic and disease-specific QOL; however, the improvement is greater in the treatment arm.”

    From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [677]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 40 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Bousquet J, Van Cauwenberge P, Khaltaev N. ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-334.

Cited by

Sorted by citations

Authors
Walter Canonica, G., Bousquet, J., Van Hammée, G., Bachert, C., Durham, S. R., Klimek, L., Mullol, J., & Van Cauwenberge, P. B.
Affiliations
  • Hôpital Arnaud de Villeneuve (FR)
  • Ghent University Hospital (BE)
  • Royal Brompton Hospital (GB)
  • Zentrum für Rhinologie und Allergologie (DE)
  • Hospital Clínic de Barcelona (ES)
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2006-10
Volume
100
Issue
10
Pages
1706-1715
ISSN
0954-6111 (ISSN-L)
OpenAlex
W2047870486
Cited by
44
References
40
Citations by year
2023: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 3 · 2012: 2
FWCI
4.67
Type
journal article
Language
en
Open access
Locations
  • Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
levocetirizine, persistent allergic rhinitis, health-related quality of life, health status, Rhinoconjunctivitis Quality of Life Questionnaire, SF-36, disease burden, patient-reported outcomes
MeSH terms
Double-Blind Method, Health Status, Humans, Piperazines, Quality of Life, Surveys and Questionnaires, Rhinitis, Allergic, Perennial, Treatment Outcome, Cetirizine, Histamine H1 Antagonists, Non-Sedating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review